<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984890</url>
  </required_header>
  <id_info>
    <org_study_id>VDBCG</org_study_id>
    <nct_id>NCT03984890</nct_id>
  </id_info>
  <brief_title>Vitamin D3 For CGD Patients With BCGosis/Itis</brief_title>
  <official_title>Effect of Vitamin D3 Supplementation on Chronic Granulomatous Disease Patients With BCGosis/Itis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      When children with chronic granulomatous disease (CGD) got BCG infection the treatment would
      be a tough task. The goal of the proposed research is to observe weather vitamin D
      supplementation can help the CGD children get through this challenge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic granulomatous disease (CGD) is one of primary immunodeficiency diseases. Due to the
      deficiency of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase the
      respiratory burst of all types of phagocytic cells is badly impaired which lead to a
      susceptibility to infection among CGD patients.

      BCG vaccine is wildly used in China to avoid severe tuberculosis infection. Children are
      supposed to get BCG vaccine injected within 24 hours after birth. When patients with CGD got
      the vaccination of BCG they will easily got infected. And due to the immunodeficiency of
      these children, the infection cannot be cure by normal treatment.

      Vitamin D supplementation was used to treat tuberculosis in the pre-antibiotic era and is
      reported to have influence on immune system especially on monocytes and macrophages thus may
      help CGD children defend the BCG infection. In addition, studies show that
      1,25-Dihydroxyvitamin D3 can induce nitric oxide synthase thus may up regulate NO production
      and help host defense against human tuberculosis without the help of NADPH oxidase. Other
      researches indicate that Vitamin D and the expression of vitamin D receptor may lead to
      induction of antimicrobial peptide such as LL-37 which help macrophages kill the
      intracellular Mycobacterium tuberculosis. These discoveries indicated that vitamin D may
      induce immune response against BCG in a nontraditional way. Therefore, when CGD patients face
      BCG infection, add vitamin D supplementation to the treatment may help them survive this
      challenge.

      Since there have had clinical trials revealing that intermittent high dose vitamin D3
      supplementation as 2.5mg per 14 days only receive positive effect on partial patients the
      investigators decide to choose a mild dose treatment as 800IU/d for 3 month to see if things
      get different in this way.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>8 weeks</time_frame>
    <description>Death rate among patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Sputum Culture acid-fast bacilli microscopy Conversion</measure>
    <time_frame>8 weeks</time_frame>
    <description>If sputum culture and acid-fast bacilli microscopy show positive results before treatments, compare the results before and after treatments to see if the rate that results changed from positive to negative differ between control group and vitamin D group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Fever</measure>
    <time_frame>8 weeks</time_frame>
    <description>Calculate the days suffer from fevers to show the severity of the infection and the efficacy of the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Anti-tuberculosis Drugs Used in the Treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Calculate the number of anti-tuberculosis drugs used in the treatment to show the severity of the infection and the efficacy of the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Protein</measure>
    <time_frame>8 weeks</time_frame>
    <description>Urine protein quantitation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Calcium</measure>
    <time_frame>8 weeks</time_frame>
    <description>Concentration of calcium in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of 25-OH Vitamin D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Concentration of 25-OH Vitamin D3 in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of Calcium</measure>
    <time_frame>8 weeks</time_frame>
    <description>Concentration of calcium in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the change in BMI by calculating weight(kg)/height(m)^2 before treatment and 1year after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Recurrent Infections</measure>
    <time_frame>1 year</time_frame>
    <description>Use frequency of recurrent infections to evaluate long-term benefits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vitamin D3</condition>
  <condition>Chronic-granulomatous Disease</condition>
  <condition>BCG</condition>
  <arm_group>
    <arm_group_label>Vitamin D Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 Supplementation plus traditional treatment of CGD and TB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Traditional treatment of CGD and TB without Vitamin D Supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 drops 800IU/d for 3 months</description>
    <arm_group_label>Vitamin D Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traditional treatment of CGD and TB</intervention_name>
    <description>Anti-tuberculosis drugs, interferon-gamma</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Vitamin D Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. less than 18 years' old

          2. Diagnosed with CGD

          3. Got BCG infection after vaccination

        Exclusion Criteria:

          1. Serum 25-(OH)-vit D &gt;75 nmol/L (30 ng/mL)

          2. Hyperphosphatemia

          3. Hypercalcemia

          4. Acute or chronic renal failure

          5. Acute or chronic cardiac failure

          6. Kidney stone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Yan, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinqiao Sun, Ph.D.,M.D</last_name>
    <phone>86-21-64932909</phone>
    <email>jinqiaosun@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Yan, Ph.D</last_name>
      <email>yanwl@fudan.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinqiao Sun, Ph.D.,M.D</last_name>
      <email>jinqiaosun@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, Davidson RN, Sørensen OE, Kampmann B, Griffiths CJ, Wilkinson RJ. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol. 2007 Jun 1;178(11):7190-8. Erratum in: J Immunol. 2007 Dec 15;179(12):8569-70.</citation>
    <PMID>17513768</PMID>
  </reference>
  <reference>
    <citation>Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun. 1998 Nov;66(11):5314-21.</citation>
    <PMID>9784538</PMID>
  </reference>
  <reference>
    <citation>Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM, Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA, Eldridge SM, Griffiths CJ. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011 Jan 15;377(9761):242-50. doi: 10.1016/S0140-6736(10)61889-2. Epub 2011 Jan 5.</citation>
    <PMID>21215445</PMID>
  </reference>
  <reference>
    <citation>Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006 Mar 24;311(5768):1770-3. Epub 2006 Feb 23.</citation>
    <PMID>16497887</PMID>
  </reference>
  <reference>
    <citation>Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.</citation>
    <PMID>30215381</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>October 19, 2019</last_update_submitted>
  <last_update_submitted_qc>October 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Jinqiao Sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

